ArticleBMC cancer2026
Evaluation of surgical approach and adjuvant therapy in uterine sarcomas: an 11-year population-based study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine sarcomas are rare and high-quality evidence regarding optimal treatment is limited and difficult to produce.
methodsA total of 618 patients with uterine sarcoma were identified in the Swedish Quality Registry for Gynecologic Cancer (SQRGC) from 2010 to 2020. Survival was analyzed according to stage, histology and treatment modality.
resultsThe incidence of uterine sarcoma was 1.43 per 100,000 woman-years. Overall survival after 1 and 5 years was 75.9% and 44.1% respectively, with survival primarily influenced by stage, age and histological type. Adjuvant chemotherapy was not associated with improved survival, neither in localized nor advanced disease. Among patients with stage I disease, overall survival was higher after minimally invasive surgery (MIS) 81%, compared to open surgery 57% (p = 0.007); however, after entropy balancing no significant difference was observed.
conclusionsMIS showed comparable survival to open surgery in early-stage uterine sarcomas, with a non-significant trend toward improved survival. Entropy balancing supported this finding but residual confounding and selection bias cannot be excluded due to the observational design. Adjuvant chemotherapy was not associated with improved survival in uterine sarcoma patients overall or in leiomyosarcomas specifically, neither in localized nor advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.